COPPER IN PEDIATRIC LIVER DISEASES
铜与小儿肝病的关系
基本信息
- 批准号:6495379
- 负责人:
- 金额:$ 17.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-12-01 至 2001-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Copper is an essential trace element with a critical role in the biochemistry of cellular respiration, antioxidant defense and iron homeostasis. The liver is the central organ of copper homeostasis in human and the long-term objective of these studies is to define the role of copper in pediatric liver disease. Recent studies have revealed that the delivery of copper to specific proteins within hepatocytes is mediated by distinct intracellular carrier proteins termed chaperones. The studies in this proposal are intended to elucidate the role of the copper chaperone HAH1 in copper trafficking and metabolism in hepatocytes. Structure/function studies will be accomplished utilizing site-directed mutagenesis and expression of HAH1 in Saccharomyces cerevisiae. The role of HAH1 in copper delivery to the secretory pathway will be examined by protein-protein interaction studies with the Wilson disease ATPase and the interaction of these proteins in intact single cell swill be examined using green fluorescent fusion proteins and fluorescence resonance energy transfer. The precise function of HAH1 in mammalian cells will be determined by analysis of copper trafficking and metabolism in the hepatocytes of mice with a targeted germline deletion of the murine HAH1 gene. Finally, the role of HAH1 in pediatric liver disease will be studied by HAH1 sequence analysis in genomic DNA from children with liver disease characterized by copper accumulation and toxicity including individuals diagnosed with Wilson disease but without detectable mutations in the Wilson ATPase. Taken together the results of these studies will permit further insight into the molecular and cellular mechanisms of copper trafficking in hepatocytes and may allow for novel therapeutic approaches to prevent or ameliorate childhood liver disease resulting from perturbations in metal metabolism.
铜是一种必需的微量元素,在细胞呼吸、抗氧化防御和铁稳态的生物化学中发挥着关键作用。肝脏是人体铜稳态的中心器官,这些研究的长期目标是明确铜在儿童肝脏疾病中的作用。最近的研究表明,铜向肝细胞内特定蛋白质的递送是由称为伴侣的不同细胞内载体蛋白介导的。本提案中的研究旨在阐明铜伴侣HAH1在肝细胞铜运输和代谢中的作用。结构/功能研究将利用酿酒酵母中 HAH1 的定点诱变和表达来完成。 HAH1 在铜输送到分泌途径中的作用将通过威尔逊病 ATP 酶的蛋白质-蛋白质相互作用研究来检查,并且使用绿色荧光融合蛋白和荧光共振能量转移检查完整单细胞泔水中这些蛋白质的相互作用。 HAH1 在哺乳动物细胞中的精确功能将通过分析小鼠肝细胞中铜的运输和代谢来确定,其中小鼠 HAH1 基因有针对性的种系缺失。最后,HAH1 在儿科肝病中的作用将通过对以铜积累和毒性为特征的肝病儿童的基因组 DNA 进行 HAH1 序列分析来研究,其中包括诊断为威尔逊病但在威尔逊 ATP 酶中未检测到突变的个体。总而言之,这些研究的结果将有助于进一步了解肝细胞中铜运输的分子和细胞机制,并可能提供新的治疗方法来预防或改善因金属代谢紊乱引起的儿童肝病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan David Gitlin其他文献
Jonathan David Gitlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan David Gitlin', 18)}}的其他基金
MECHANISMS OF GROWTH AND THE OVERGROWTH SYNDROMES
生长机制和过度生长综合症
- 批准号:
6895276 - 财政年份:2001
- 资助金额:
$ 17.56万 - 项目类别:
MECHANISMS OF GROWTH AND THE OVERGROWTH SYNDROMES
生长机制和过度生长综合症
- 批准号:
6737561 - 财政年份:2001
- 资助金额:
$ 17.56万 - 项目类别:
MECHANISMS OF GROWTH AND THE OVERGROWTH SYNDROMES
生长机制和过度生长综合症
- 批准号:
6536286 - 财政年份:2001
- 资助金额:
$ 17.56万 - 项目类别:
MECHANISMS OF GROWTH AND THE OVERGROWTH SYNDROMES
生长机制和过度生长综合症
- 批准号:
6288561 - 财政年份:2001
- 资助金额:
$ 17.56万 - 项目类别:
MECHANISMS OF GROWTH AND THE OVERGROWTH SYNDROMES
生长机制和过度生长综合症
- 批准号:
6638003 - 财政年份:2001
- 资助金额:
$ 17.56万 - 项目类别:
相似海外基金
The pathogenesis of ALG14-congenital disorders of glycosylation.
ALG14-先天性糖基化障碍的发病机制。
- 批准号:
23K14967 - 财政年份:2023
- 资助金额:
$ 17.56万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying New Therapeutics and Molecular Mechanisms in Congenital Disorders of Glycosylation.
确定先天性糖基化疾病的新疗法和分子机制。
- 批准号:
10644811 - 财政年份:2023
- 资助金额:
$ 17.56万 - 项目类别:
Investigating the Genotype-Phenotype Relationships that Underlie Congenital Disorders with Cardiovascular Symptoms through Population-scale Analyses
通过人群规模分析研究具有心血管症状的先天性疾病背后的基因型-表型关系
- 批准号:
10724185 - 财政年份:2023
- 资助金额:
$ 17.56万 - 项目类别:
Identifying understudied protein-related glycoproteome disruption in Congenital Disorders of Glycosylation
识别先天性糖基化障碍中尚未研究的蛋白质相关糖蛋白组破坏
- 批准号:
10725869 - 财政年份:2023
- 资助金额:
$ 17.56万 - 项目类别:
Pathogenic Mechanisms of Congenital Disorders of Glycosylation
先天性糖基化障碍的发病机制
- 批准号:
10633548 - 财政年份:2023
- 资助金额:
$ 17.56万 - 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10480649 - 财政年份:2022
- 资助金额:
$ 17.56万 - 项目类别:
Assessment of a potential application of endogenous stem cells to treat congenital disorders
评估内源干细胞治疗先天性疾病的潜在应用
- 批准号:
22K20740 - 财政年份:2022
- 资助金额:
$ 17.56万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10616658 - 财政年份:2022
- 资助金额:
$ 17.56万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10040788 - 财政年份:2020
- 资助金额:
$ 17.56万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10250486 - 财政年份:2020
- 资助金额:
$ 17.56万 - 项目类别: